The inhibition of monoacylglycerol lipase by URB602 showed an anti‐inflammatory and anti‐nociceptive effect in a murine model of acute inflammation
Open Access
- 1 November 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (5) , 787-794
- https://doi.org/10.1038/sj.bjp.0707425
Abstract
Background and purpose: 2‐arachidonoylglycerol (2‐AG) is an endocannabinoid whose hydrolysis is predominantly catalysed by the enzyme monoacylglycerol lipase (MAGL). The development of MAGL inhibitors could offer an opportunity to investigate the anti‐inflammatory and anti‐nociceptive role of 2‐AG, which have not yet been elucidated. On these bases, URB602, a MAGL inhibitor, was tested in a murine model of inflammation/inflammatory pain.Experimental approach: Acute inflammation was induced by intraplantar injection of λ‐carrageenan into mice. The highest dose to be employed has been selected performing the tetrad assays for cannabimimetic activity in mice. URB602 anti‐inflammatory and anti‐nociceptive efficacy (assessed by plethysmometer and plantar test, respectively) was evaluated both in a preventive regimen (drug administered 30 min before carrageenan) and in a therapeutic regimen (URB602 administered 30 min after carrageenan). To elucidate the cannabinoid receptor involvement, rimonabant and SR144528, CB1and CB2selective antagonists, respectively, were given 15 min before URB602.Key results: Systemic administration of URB602 elicited a dose‐dependent anti‐oedemigen and anti‐nociceptive effect that was reversed exclusively by the CB2receptor antagonist. The efficacy of URB602 persisted also when the compound was administered in a therapeutic regimen, suggesting the ability of URB602 to improve established disease.Conclusions and implications: The present report highlighted the ability of the selective MAGL inhibitor, URB602, to prevent and treat an acute inflammatory disease without producing adverse psychoactive effects. The data presented herein also contributed to clarify the physiological role of 2‐AG in respect to inflammatory reactions, suggesting its protective role in the body.British Journal of Pharmacology(2007)152, 787–794; doi:10.1038/sj.bjp.0707425; published online 13 August 2007Keywords
This publication has 34 references indexed in Scilit:
- Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J miceEuropean Journal of Pharmacology, 2007
- Identification of a Novel Endocannabinoid-Hydrolyzing Enzyme Expressed by Microglial CellsJournal of Neuroscience, 2007
- The antinociceptive effects of intraplantar injections of 2‐arachidonoyl glycerol are mediated by cannabinoid CB2receptorsBritish Journal of Pharmacology, 2007
- Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesiaNeuropharmacology, 2006
- Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampusNature Neuroscience, 2005
- Interactions between the CB1 receptor agonist Δ9-THC and the CB1 receptor antagonist SR-141716 in rats: Open-field revisitedPharmacology Biochemistry and Behavior, 2002
- Despite substantial degradation, 2‐arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor‐dependent G‐protein activation in rat cerebellar membranesBritish Journal of Pharmacology, 2001
- Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid ReceptorScience, 1992
- A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesiaPAIN®, 1988
- Ethical guidelines for investigations of experimental pain in conscious animalsPAIN®, 1983